FrancophonIA/ELRC3.0 huggingface dataset:
English: Common side effects (may affect up to 1 in 10 people) - low heart beat (bradycardia) - psychotic behaviour (mental illness with hallucinations, difficulty in thinking clearly and understanding reality, anxiety), initial difficulty in sleeping - confused state, fainting, tremor, dizziness, headache - intestinal (abdominal) pain, irritation of the stomach caused by digestive acids (reflux gastritis),
Slovenian: Pogosti neželeni učinki (lahko prizadenejo največ 1 od 10 bolnikov) - nizek srčni utrip (bradikardija) - psihotično vedenje (psihična bolezen s halucinacijami, oteženo jasno razmišljanje in razumevanje realnosti, anksioznost), začetne težave s spanjem
English: Lamzede 10 mg powder for solution for infusion velmanase alfa
Slovenian: Lamzede 10 mg prašek za raztopino za infundiranje velmanaza alfa
English: Feeling hot(1)
Slovenian: občutek vročine(1)
English: Each mL of reconstituted solution contains 2 mg of velmanase alfa.
Slovenian: En ml rekonstituirane raztopine vsebuje 2 mg velmanaze alfa.
English: Appropriate medical support should be readily available when velmanase alfa is administered.
Slovenian: Pri uporabi velmanaze alfa mora biti nujno na voljo ustrezna zdravniška podpora.
English: Pharmacodynamic
Slovenian: Farmakodinamika
English: One vial contains 10 mg of velmanase alfa*.
Slovenian: Ena viala vsebuje 10 mg velmanaze alfa*.
English: Lamzede is a white to off-white powder for solution for infusion, supplied in a glass vial.
Slovenian: Zdravilo Lamzede bel do belkast prašek za raztopino za infundiranje, ki je na voljo v stekleni viali.
English: A volume of 10 mL sodium chloride solution should be administered through the infusion system to infuse the remaining fraction of Lamzede in the line to the patient.
Slovenian: Preostali del zdravila Lamzede je bolniku treba infundirati tako, da mu aplicirate 10 ml raztopine natrijevega klorida s sistemom za infundiranje.
English: Reconstituted solution for infusion
Slovenian: 3 leti Rekonstituirana raztopina za infundiranje
English: Lamzede contains sodium
Slovenian: Zdravilo Lamzede vsebuje natrij
English: Nausea(1)
Slovenian: bruhanje(1)
English: Antibodies may play a role in treatment-related reactions observed with the use of velmanase alfa.
Slovenian: Pri reakcijah, povezanih z zdravljenjem, o katerih so poročali pri uporabi velmanaze alfa, lahko igrajo vlogo protitelesa.
English: nausea, vomiting - pain at the site the infusion is given, chills, feeling hot, malaise, tiredness (fatigue) - skin rashes (urticaria), increased sweating (hyperhidrosis) - nosebleed - joint pain, back pain, joint stiffness, muscle pain, pain in extremity (hands, feet) - eye irritation, eyelid swelling (eyelid oedema), eye redness - increased appetite
Slovenian: - bolečine v sklepih, bolečine v hrbtu, okorelost sklepov, bolečine v mišicah, bolečine v okončinah (rokah, nogah) - draženje oči, otekanje vek (edem vek), pordelost oči - povečan apetit
English: One vial contains 10 mg of velmanase alfa.
Slovenian: Ena viala vsebuje 10 mg velmanaze alfa.
English: Common side effects (may affect up to 1 in 10 people) - loss of consciousness (fainting, which may be preceded by feeling dizzy, lightheaded or confused) - acute renal insufficiency (kidney problems which can be recognised from fluid retention, swelling in legs, ankles or feet, drowsiness, shortness of breath or fatigue) - hypersensitivity and serious allergic reaction (symptoms including localised or diffuse skin itching, dizziness, difficulty breathing, chest pain, gastrointestinal symptoms such as nausea, vomiting, diarrhea or intestinal pain, swelling of the throat, face, lips or tongue)
Slovenian: - preobčutljivost in resna alergijska reakcija (simptomi, ki vključujejo lokalno ali razpršeno kožno srbečico, vrtoglavico, težave z dihanjem, bolečine v prsnem košu, prebavne simptome, kot so siljenje na bruhanje, bruhanje ali črevesne bolečine, otekanje žrela, obraza, ustnic ali jezika)
English: IRRs (including hypersensitivity, nausea, vomiting, pyrexia, chills, feeling hot, malaise, urticaria, anaphylactoid reaction and hyperhidrosis) were reported in 9% of the patients (3 out of 33 patients) in clinical studies.
Slovenian: Pri 9 % bolnikov (3 od 33 bolnikov) v kliničnih študijah so poročali o IRR (vključno s preobčutljivostjo, navzeo, bruhanjem, pireksijo, mrzlico, občutkom vročine, neugodjem, urtikarijo, anafilaktoidno reakcijo in hiperhidrozo).
English: If you experience any side effect like these, please tell your doctor immediately.
Slovenian: Če doživite katerega od teh neželenih učinkov, se nemudoma posvetujte z zdravnikom.
English: Contents of the pack and other information
Slovenian: Shranjevanje zdravila Lamzede Vsebina pakiranja in dodatne informacije
English: Very common side effects (may affect more than 1 in 10 people) - diarrhoea - weight increase - fever/increased body temperature
Slovenian: - povečanje telesne mase - povišanje telesne temperature/vročina
English: The patient should be kept under observation for IRRs for one hour or longer after the infusion, according to the treating physician's judgement.
Slovenian: Glede na presojo zdravnika, je treba bolnika opazovati glede morebitnih IRR eno uro po infundiranju ali dlje.
English: Pharmacodynamic Domain Response
Slovenian: Odziv na področju farmakodinamike Oligosaharidi
English: STATEMENT OF ACTIVE SUBSTANCE(S)
Slovenian: Povprečna vrednost (SD)
English: [95% CI] p-value p=0.406
Slovenian: Vrednost p p = 0,406
English: Administration of Lamzede should be carried out by a healthcare professional with the ability to manage ERT and medical emergencies.
Slovenian: Zdravilo Lamzede mora dati zdravstveni delavec, ki obvladuje
English: White to off-white powder.
Slovenian: prašek za raztopino za infundiranje Prašek bele do belkaste barve.
English: <18 years(2) ≥18 years(2) 3MSCT (steps/min) Overall(1)
Slovenian: 3MSCT (koraki/min) Celokupna vrednost(1)
English: Statistically significant improvements were detected in serum oligosaccharide levels, 3MSCT, pulmonary function, serum IgG
Slovenian: Do zadnjega opazovanja so ugotovili statistično značilna izboljšanja v koncentracijah oligosaharidov v serumu, vrednosti 3MSCT, pljučni funkciji, koncentraciji IgG v serumu ter indeksu zdravja EQ-5D-5L (euro quality of life-5 dimensions) v daljšem časovnem obdobju (preglednica 3).
English: Malaise(1)
Slovenian: utrujenost neugodje(1)
English: Renal or hepatic impairment
Slovenian: sinkopa tremor vrtoglavica glavobol
English: Initial insomnia
Slovenian: Psihiatrične motnje psihotično vedenje začetna nespečnost
English: Anaphylactoid reaction(1)
Slovenian: anafilaktoidna reakcija(1)
English: Chiesi Pharmaceuticals B.V. Tel: + 31 88 501 64 00
Slovenian: Tel: + 31 88 501 64 00
English: [95% CI] p-value p<0.001
Slovenian: Vrednost p p < 0,001
English: Functional Domain Response Combined
Slovenian: Odziv na področju funkcije
English: <18 years(2) ≥18 years(2) FVC (% of predicted) Overall(1)
Slovenian: FVC (% predvidene) Celokupna vrednost(1)
English: <18 years(2) ≥18 years(2) 6MWT (metres) Overall(1)
Slovenian: 6MWT (metri) Celokupna vrednost(1)
English: Eyelid oedema
Slovenian: OVOJNINAH NALEPKA VIALE
English: In the clinical studies at any time under treatment, 8 patients out of 33 (24%) developed IgG-class antibodies to velmanase alfa.
Slovenian: V kliničnih študijah so se v času zdravljenja pri 8 bolnikih od 33
English: Hypersensitivity(1)
Slovenian: Bolezni imunskega sistema preobčutljivost(1)
English: Pregnancy and breast-feeding
Slovenian: siljenje na bruhanje, bruhanje
English: Musculoskeletal and connective tissue disorders
Slovenian: Jasne povezave med titri protiteles
English: SPECIFIC OBLIGATION TO COMPLETE POSTAUTHORISATION MEASURES FOR THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES
Slovenian: SPECIFIČNE ZAHTEVE ZA IZPOLNITEV UKREPOV PO
English: Strength Pharmaceutical Form Route of administration Packaging
Slovenian: Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina velikost pakiranja
English: Strength Pharmaceutical Form
Slovenian: Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina velikost pakiranja
English: Ref.: EMEA/CHMP/643056/2009 EMEA/H/C/805
Slovenian: EMEA/CHMP/643048/2009 EMEA/H/C/805
English: This summary was last updated in 09-2009.
Slovenian: Povzetek je bil nazadnje posodobljen 09-2009.
English: They can be taken with or without food.
Slovenian: Lahko se vzamejo s hrano ali brez nje.
English: At the start of the study, the patients could exercise for about 7 minutes.
Slovenian: Na začetku študije so lahko bolniki telovadili približno 7 minut.
English: 1 Previously known as Latixa.
Slovenian: 1 Prej znano kot Latixa.
English: The marketing authorisation holder is Menarini International Operations Luxembourg S.A.
Slovenian: Imetnik dovoljenja za promet z zdravilom je družba Menarini International Operations Luxembourg S.A.
English: The main measure of effectiveness was how long patients could exercise after 12 weeks of treatment, compared with before treatment.
Slovenian: Glavno merilo učinkovitosti je bil čas, kako dolgo so lahko bolniki telovadili po 12tedenskem zdravljenju, v primerjavi s časom pred zdravljenjem.
English: The name of the medicine was changed to Ranexa on 11 August 2008.
Slovenian: Ime zdravila je bilo 11. avgusta 2008 spremenjeno v Ranexa.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Latixa on 9 July 2008.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Latixa, veljavno po vsej Evropski uniji, odobrila družbi dne 9. julija 2008.
English: It is available as oval prolongedrelease tablets (blue: 375 mg; orange: 500 mg; green: 750 mg).
Slovenian: Na voljo je v obliki ovalnih tablet s podaljšanim sproščanjem (modrih: 375 mg; oranžnih: 500 mg; zelenih: 750 mg).
English: Ranexa tablets should be swallowed whole and should not be broken, crushed or chewed.
Slovenian: Tablete Ranexa je treba pogoltniti cele in se jih ne sme prelomiti, zdrobiti ali žvečiti.
English: Ranexa was more effective than placebo at increasing the length of time the patients could exercise.
Slovenian: Zdravilo Ranexa je bilo učinkovitejše od placeba pri povečevanju dolžine časa, ko so bolniki lahko telovadili.
English: Other information about Ranexa:
Slovenian: Druge informacije o zdravilu Ranexa:
English: The card will be inserted in the boxes containing the tablets and will include information for patients and healthcare workers explaining how to use the medicine safely.
Slovenian: Kartica bo priložena škatlici s tabletami in bo vsebovala informacije za bolnike in zdravstvene delavce o varni uporabi zdravila.
English: After two to four weeks, the dose should be increased to 500 mg twice a day, and then to 750 mg twice a day, depending on the patient's response.
Slovenian: Po dveh do štirih tednih je treba odmerek povečati na 500 mg dvakrat na dan in nato na 750 mg dvakrat na dan, odvisno od bolnikovega odziva.
English: Ranexa has been studied in one main study including a total of 823 patients with an average age of 64 years who had had angina pectoris for at least three months.
Slovenian: Zdravilo Ranexa so proučevali v eni glavni študiji, v katero je bilo skupaj vključenih 823 bolnikov povprečne starosti 64 let, ki so imeli angino pektoris vsaj tri mesece.
English: ‘Prolonged release' means that ranolazine is released slowly from the tablet over a few hours.
Slovenian: „Podaljšano sproščanje“ pomeni, da se ranolazin iz tablet počasi sprošča več ur.
English: Which measures are being taken to ensure the safe use of Ranexa?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Ranexa?
English: ranolazine EPAR summary for the public
Slovenian: Povzetek EPAR za javnost
English: This interferes with the activity of special channels on the cell surface called ‘sodium-dependent calcium channels' through which calcium ions normally enter the cells.
Slovenian: To ovira delovanje posebnih kanalčkov na površini celice, imenovanih „od natrija odvisni kalcijevi kanalčki“, skozi katere kalcijevi ioni običajno vstopajo v celico.
English: Dose increases should be carried out carefully in the elderly, in patients who weigh less than 60 kg, and in patients who have problems with their kidneys, liver or heart.
Slovenian: Odmerek je treba previdno povečevati pri starejših ljudeh, bolnikih, ki tehtajo manj kot 60 kg, in bolnikih, ki imajo težave z ledvicami, jetri ali srcem.
English: This reduces the number of calcium ions that enter the cells.
Slovenian: Tako se zniža število kalcijevih ionov, ki vstopajo v celice.
English: The company that makes Ranexa will agree on the wording of the patient alert card in each Member State.
Slovenian: Družba, ki izdeluje zdravilo Ranexa, se bo dogovorila o besedilu opozorilne kartice za bolnike v posameznih državah članicah.
English: It must also not be used in patients who are taking other medicines that are broken down in the same way as ranolazine, or certain other medicines that are used to correct the heart rhythm.
Slovenian: Prav tako se ne sme uporabljati pri bolnikih, ki jemljejo druga zdravila, ki se razgrajujejo enako kot ranolazin, ali nekatera druga zdravila, ki se uporabljajo za uravnavanje srčnega ritma.
English: Ranexa is a medicine that contains the active substance ranolazine.
Slovenian: Ranexa je zdravilo, ki vsebuje zdravilno učinkovino ranolazin.
English: The recommended starting dose of Ranexa is 375 mg twice a day.
Slovenian: Priporočeni začetni odmerek zdravila Ranexa je 375 mg dvakrat na dan.
English: The Committee recommended that Ranexa be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Ranexa odobri dovoljenje za promet.
English: What benefit has Ranexa shown during the studies?
Slovenian: Kakšne koristi je zdravilo Ranexa izkazalo med študijami?
English: Two doses of Ranexa (750 and 1000 mg twice a day) were compared with placebo (a dummy treatment) as an add-on to commonly used medicines for angina pectoris (atenolol, amlodipine or diltiazem).
Slovenian: Dva odmerka zdravila Ranexa (750 in 1000 mg dvakrat na dan) so primerjali s placebom (zdravilom brez zdravilne učinkovine) kot dodatek k običajno uporabljenim zdravilom za zdravljenje angine pektoris (atenolol, amlodipin ali diltiazem).
English: After 12 weeks, this increased by an average of 1 minute 56 seconds in the patients adding either dose of Ranexa, and by an average of 1 minute 32 seconds in those adding placebo.
Slovenian: Po 12 tednih se je ta čas pri bolnikih, ki so prejemali kateri koli odmerek zdravila Ranexa, povprečno povečal za 1 minuto in 56 sekund in za povprečno 1 minuto in 32 sekund pri tistih, ki so prejemali placebo.
English: Ranexa should not be used in people who may be hypersensitive (allergic) to ranolazine or any of the other ingredients.
Slovenian: Zdravila Ranexa ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) ranolazin ali katero koli drugo sestavino zdravila.
English: The most common side effects with Ranexa (seen in between 1 and 10 patients in 100) are dizziness, headache, constipation, vomiting, nausea (feeling sick) and asthenia (weakness).
Slovenian: Najpogostejši neželeni učinki zdravila Ranexa (opaženi pri 1 do 10 bolnikov izmed 100) so omotica, glavobol, zaprtje, bruhanje, navzeja (slabost) in astenija (oslabelost).
English: The Committee for Medicinal Products for Human Use (CHMP) noted that the effectiveness of Ranexa in improving the symptoms of patients with stable angina pectoris is modest but that it could be of value in patients who have not responded fully to other medicines.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je opozoril, da je učinkovitost zdravila Ranexa pri lajšanju simptomov pri bolnikih s stabilno angino pektoris zmerna, a bi lahko bila koristna pri bolnikih, ki se niso popolnoma odzvali na druga zdravila.
English: For the full list of these medicines, see the Package Leaflet.
Slovenian: Za celoten seznam teh zdravil glejte navodilo za uporabo.
English: It must not be used in patients who have severe problems with their kidneys or moderate or severe problems with their liver.
Slovenian: Ne smejo ga uporabljati niti bolniki, ki imajo hude težave z ledvicami oziroma zmerne ali hude težave z jetri.
English: It is used as an add-on to existing treatment in patients whose disease is not adequately controlled by other medicines for angina pectoris, such as beta-blockers or calcium antagonists, or in patients who cannot take these medicines.
Slovenian: Uporablja se kot dodatek k obstoječemu zdravljenju pri bolnikih, pri katerih bolezen ni ustrezno nadzorovana z drugimi zdravili za zdravljenje angine pektoris, kot so zaviralci receptorjev beta ali antagonisti kalcija, ali pri bolnikih, ki ne smejo jemati teh zdravil.
English: Patients who take Ranexa must be given a ‘patient alert card' that summarises the key safety information on the medicine.
Slovenian: Bolnikom, ki jemljejo zdravilo Ranexa, je treba dati posebno opozorilno kartico, ki povzema najpomembnejše informacije o varnosti zdravila.
English: Ranexa is used to treat the symptoms of stable angina pectoris (chest pain caused by reduced blood flow to the heart).
Slovenian: Zdravilo Ranexa se uporablja za zdravljenje simptomov stabilne angine pektoris (bolečin v prsih, ki jih povzroča zmanjšan dotok krvi v srce).
English: By reducing the flow of calcium into the cells, ranolazine is thought to help the heart to relax, improving blood flow to the heart muscle and relieving the symptoms of angina pectoris.
Slovenian: Ranolazin naj bi z zmanjševanjem pretoka kalcija v celice pomagal pri sprostitvi srca, izboljšal pretok krvi v srčno mišico in ublažil simptome angine pektoris.
English: What is the risk associated with Ranexa?
Slovenian: Kakšna tveganja so povezana z zdravilom Ranexa?
English: For the full list of all side effects reported with Ranexa, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Ranexa, glejte navodilo za uporabo.
English: Calcium ions normally cause the heart muscle to contract.
Slovenian: Kalcijevi ioni običajno povzročajo krčenje srčne
English: The full EPAR for Ranexa can be found here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ranexa je na voljo tukaj.
English: The active substance in Ranexa, ranolazine, is thought to work by reducing the flow of sodium ions into the heart muscle cells.
Slovenian: Zdravilna učinkovina zdravila Ranexa, ranolazin, naj bi delovala tako, da znižuje pretok natrijevih ionov v celice srčne mišice.
English: Why has Ranexa been approved?
Slovenian: Zakaj je bilo zdravilo Ranexa odobreno?
English: The Committee decided that Ranexa's benefits are greater than its risks as an add-on treatment of the symptoms of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal medicines (such as beta-blockers and/or calcium antagonists).
Slovenian: Odbor je zaključil, da so koristi zdravila Ranexa kot dodatek k zdravljenju simptomov pri bolnikih s stabilno angino pektoris, katerih bolezen ni ustrezno nadzorovana ali ki se ne odzivajo na antianginozna zdravila prve izbire (kot so zaviralci receptorjev beta in antagonisti kalcija), večje od z njim povezanih tveganj.
English: What is Ranexa used for?
Slovenian: Za kaj se zdravilo Ranexa uporablja?
English: How is Ranexa used?
Slovenian: Kako se zdravilo Ranexa uporablja?
English: How has Ranexa been studied?
Slovenian: Kako je bilo zdravilo Ranexa raziskano?
English: Doses may need to be lower in patients who have certain side effects.
Slovenian: Najvišji odmerek je 750 mg dvakrat na dan. Odmerke bo morda treba zmanjšati pri bolnikih, pri katerih se pojavijo nekateri neželeni učinki.
English: What is Ranexa?
Slovenian: Kaj je zdravilo Ranexa?
English: How does Ranexa work?
Slovenian: Kako zdravilo Ranexa deluje?
English: Prazitel Plus was first launched in the EU market in May 2009.
Slovenian: Zdravilo Prazitel Plus je prvič prišlo na trg EU maja 2009.
English: Member State EU/EEA
Slovenian: Država članica EU/EEA
English: Nematodes:
Slovenian: Nematodi:
English: Since first marketing, the product has been shown to be well tolerated (very few reports of adverse effects) and there have been no reports of suspected lack of expected efficacy.
Slovenian: Od prvega trženja naprej se je izkazalo, da se izdelek dobro prenaša (zelo malo poročil o neželenih učinkih) in ni bilo nobenih poročil o domnevnem pomanjkanju pričakovane učinkovitosti.
English: ATC vet code: QP52AA51
Slovenian: Oznaka ATC vet : QP52AA51
English: A pale yellow tablet with a cross breakline on one side.
Slovenian: Bledo rumena tableta s prelomno linijo na eni strani.
English: Excipients: For a full list of excipients, see section 6.1.
Slovenian: Pomožne snovi: Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
English: The tablets can be divided into equal halves or equal quarters.
Slovenian: Tableta se lahko razdeli na enaki polovici ali enake četrtine.
English: Discussion of the data available
Slovenian: Razprava o razpoložljivih podatkih
English: After absorption, the drug is distributed to all organs.
Slovenian: Po absorbciji se zdravilo prenese v vse organe.
English: PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable.
Slovenian: PREPOVED PRODAJE, OSKRBE IN/ALI UPORABE Navedba ni smiselna
English: Therefore, use of the product to eliminate the target parasites will benefit both the treated animal and public health.
Slovenian: Zato uporaba zdravila za odpravo ciljnih parazitov koristi tako zdravljeni živali kot tudi javnemu zdravju.
English: Labelling
Slovenian: Označevanje
English: Further, it is considered that use of this product, in accordance with label recommendations in the product literature, sufficiently manages the risk associated with its use.
Slovenian: Poleg tega velja, da uporaba tega zdravila v skladu s priporočili na etiketi v strokovni literaturi o zdravilu v zadostni meri obvladuje tveganje, povezano z njegovo uporabo.
English: The target parasites have the potential to impact on welfare of individual infected animals.
Slovenian: Ciljni paraziti lahko vplivajo na dobro počutje posameznih okuženih živali.
English: None known.
Slovenian: Niso poznani.
English: This conclusion is in line with the view taken during the various mutual recognition procedures (IE/V/0241-0243/001/MR).
Slovenian: Ta zaključek je v skladu s stališčem v različnih postopkih z medsebojnim priznavanjem (IE/V/02410243/001/MR).
English: Pyrantel acts as a cholinergic agonist.
Slovenian: Pirantel deluje kot holinergični agonist.
English: In addition, a number of the target parasites have the potential to infect humans (zoonotic potential).
Slovenian: Poleg tega lahko številni ciljni paraziti okužijo ljudi (možnost zoonotskega prenosa).
English: Formation of microtubules is thereby prevented, resulting in disruption of structures vital to the normal functioning of the helminth.
Slovenian: S tem je preprečeno nastajanje mikrotubulov, kar ima za posledico motnjo v strukturi, ki je vitalna za normalno funkcioniranje helmintov.
English: The product is not expected to pose a risk to the user when used in accordance with label recommendations.
Slovenian: To zdravilo naj ne bi predstavljajo tveganja za uporabnika, če se uporablja v skladu z priporočili na etiketi.
English: No studies have been performed in dogs during early pregnancy.
Slovenian: V obdobju zgodnje brejosti niso bile opravljene študije pri psih.
English: The reference product is authorised for use from two weeks of age with no specific risk identified for this particular age group.
Slovenian: Referenčno zdravilo je odobreno za uporabo od drugega tedna starosti brez posebnega tveganja za to starostno skupino.
English: Do not use simultaneously with piperazine compounds.
Slovenian: Ne uporabite istočasno z zdravili s piperazinom.
English: The tablets can be given directly to the dog or disguised in food.
Slovenian: Tablete lahko dajete psu neposredno ali skrite v hrani.
English: This rapid contraction has been explained by changes in divalent cation fluxes, especially calcium.
Slovenian: Hitre kontrakcije so posledica sprememb v fluksih divalentnih kationov, posebej kalcija.